Inventiva
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 20, 2027The maintenance fee for Ppar Compounds for Use in the Treatment of Fibrotic Diseases (US 10,383,858) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Compounds as inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma (US 10,414,739) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Crystal Form of Lanifibranor, Preparation Method Therefor, and Use Thereof (US 11,827,630) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,795,297 | Indole Compounds, Method of Preparing Them and Uses Thereof In force · High confidence | In force | High confidence | |
| US 7,652,032 | 5-Thioxylopyranose compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 8,436,040 | Method of Treating Conditions Involving Ppar-Receptors with Indole Compounds In force · High confidence | In force | High confidence | |
| US 9,561,246 | Use of Odiparcil in the treatment of a mucopolysaccharidosis In force · From the USPTO record | In force | From the USPTO record | |
| US 10,092,540 | Method of treatment of a mucopolysaccharidosis In force · From the USPTO record | In force | From the USPTO record | |
| US 10,052,311 | Ppar Compounds for Use in the Treatment of Fibrotic Diseases In force · High confidence | In force | High confidence | |
| US 10,383,858 | Ppar Compounds for Use in the Treatment of Fibrotic Diseases In force · High confidence | In force | High confidence | |
| US 10,414,739 | Compounds as inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma In force · From the USPTO record | In force | From the USPTO record | |
| US 11,504,380 | Method of Treatment of Cirrhosis In force · High confidence | In force | High confidence | |
| US 11,999,758 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 13: 8 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 1 abandoned · 3 no status recorded